1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence : A Nested Case-Control Study
(
- Contribution to journal › Article
- 2018
-
Mark
Interactions between ABCB1genotype and preoperative statin use impact clinical outcomes among breast cancer patients
(
- Contribution to journal › Article
-
Mark
Increasing preoperative body size in breast cancer patients between 2002 and 2016 : implications for prognosis
(
- Contribution to journal › Article
-
Mark
Coffee is associated with lower breast tumor insulin-like growth factor receptor 1 levels in normal-weight patients and improved prognosis following tamoxifen or radiotherapy treatment
(
- Contribution to journal › Article
- 2017
-
Mark
The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size
(
- Contribution to journal › Article
-
Mark
Combined and individual tumor-specific expression of insulinlike growth factor-I receptor, insulin receptor and phosphoinsulin- like growth factor-I receptor/insulin receptor in primary breast cancer : Implications for prognosis in different treatment groups
(
- Contribution to journal › Article
-
Mark
Body mass index influences the prognostic impact of combined nuclear insulin receptor and estrogen receptor expression in primary breast cancer
(
- Contribution to journal › Article
- 2012
-
Mark
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study
(
- Contribution to journal › Article
- 2011
-
Mark
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
(
- Contribution to journal › Article
-
Mark
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
(
- Contribution to journal › Article